Table 1.
Patient and treatment characteristics
| Variable | Control group n = 31 | Intervention group n = 31 | p |
|---|---|---|---|
| Age, median (IQR), years | 55 (47–62) | 56 (51–61) | 0.573a |
| Stage | 0.725b | ||
| I | 1 (3%) | 0 (0%) | |
| II | 17 (55%) | 14 (45%) | |
| III | 11 (36%) | 15 (48%) | |
| IV | 2 (6%) | 2 (7%) | |
| Treatment | 0.828b | ||
| AC | 2 (7%) | 3 (10%) | |
| AC-T | 19 (61%) | 21 (68%) | |
| FAC | 8 (26%) | 6 (19%) | |
| No chemotherapy | 2 (6%) | 1 (3%) | |
| Techniques | 0.99b | ||
| 3D-CRT | 21 (68%) | 22 (71%) | |
| TomoTherapy | 10 (32%) | 9 (29%) | |
| Skin dose, mean ± SD, Gy | 47.99 ± 3.09 | 47.83 ± 3.15 | 0.725a |
| Dmax, mean ± SD, Gy | 50.39 ± 3.39 | 49.76 ± 3.38 | 0.460a |
| Chest wall separation, mean ± SD, cm | 19.90 ± 2.86 | 19.72 ± 2.82 | 0.683a |
IQR, Interquartile range; AC, anthracycline and cyclophosphamide; T, taxane; FAC, 5-fluorouracil, anthracycline, and cyclophosphamide; 3D-CRT, 3-dimensional conformal radiotherapy.
a
Wilcoxon rank-sum test.
b
Fisher's exact test.